UniSa - IRIS Institutional Research Information System

PICILLO, Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.969
NA - Nord America 11.367
EU - Europa 4.167
SA - Sud America 1.201
Continente sconosciuto - Info sul continente non disponibili 507
AF - Africa 144
OC - Oceania 70
Totale 34.425
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 12.234
US - Stati Uniti d'America 10.859
SG - Singapore 2.099
IT - Italia 1.818
CN - Cina 951
BR - Brasile 939
VN - Vietnam 724
RU - Federazione Russa 504
UA - Ucraina 349
DE - Germania 291
CA - Canada 236
FR - Francia 235
IE - Irlanda 233
KR - Corea 195
TR - Turchia 178
SE - Svezia 161
GB - Regno Unito 156
BD - Bangladesh 135
IN - India 110
AR - Argentina 94
FI - Finlandia 76
EE - Estonia 70
MX - Messico 69
NL - Olanda 63
JP - Giappone 59
IQ - Iraq 48
AU - Australia 43
CO - Colombia 43
PL - Polonia 43
ES - Italia 40
ZA - Sudafrica 37
EC - Ecuador 34
PK - Pakistan 34
VE - Venezuela 33
CR - Costa Rica 30
IL - Israele 28
AT - Austria 25
ID - Indonesia 25
NZ - Nuova Zelanda 25
CZ - Repubblica Ceca 23
JM - Giamaica 23
UZ - Uzbekistan 22
MA - Marocco 21
GT - Guatemala 20
KE - Kenya 18
PR - Porto Rico 18
NI - Nicaragua 17
GP - Guadalupe 16
SV - El Salvador 16
PY - Paraguay 15
CL - Cile 13
HN - Honduras 13
MY - Malesia 13
SA - Arabia Saudita 13
TT - Trinidad e Tobago 13
UY - Uruguay 12
BO - Bolivia 11
DZ - Algeria 11
LT - Lituania 11
PH - Filippine 11
SC - Seychelles 11
NP - Nepal 10
OM - Oman 10
CH - Svizzera 9
KZ - Kazakistan 9
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
BS - Bahamas 7
DO - Repubblica Dominicana 7
EG - Egitto 7
ET - Etiopia 7
JO - Giordania 7
LB - Libano 7
PA - Panama 7
TN - Tunisia 7
BE - Belgio 6
BG - Bulgaria 6
PE - Perù 6
AL - Albania 5
CW - ???statistics.table.value.countryCode.CW??? 5
MK - Macedonia 5
MN - Mongolia 5
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
LK - Sri Lanka 4
PT - Portogallo 4
RS - Serbia 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BY - Bielorussia 3
GE - Georgia 3
KG - Kirghizistan 3
LU - Lussemburgo 3
LY - Libia 3
MD - Moldavia 3
NO - Norvegia 3
AM - Armenia 2
BH - Bahrain 2
BW - Botswana 2
Totale 33.870
Salva come PNG Salva come JPEG
Città #
Hong Kong 12.219
San Jose 1.555
Ann Arbor 1.168
Singapore 988
Ashburn 763
Milan 737
Princeton 614
Dallas 535
Chandler 521
Wilmington 472
Council Bluffs 448
Jacksonville 415
Houston 313
Beijing 248
Dublin 225
New York 199
The Dalles 193
Lauterbourg 192
Ho Chi Minh City 183
Woodbridge 182
Rome 173
Los Angeles 167
Santa Clara 157
Dong Ket 144
Izmir 143
Hanoi 142
Moscow 125
Naples 125
Andover 117
Nanjing 109
São Paulo 88
Boardman 82
Pellezzano 76
Figino 71
Phoenix 70
Salerno 69
Tallinn 69
Buffalo 68
Norwalk 64
Munich 55
Tokyo 52
Dearborn 47
Düsseldorf 46
Montreal 46
Chicago 45
Shenyang 44
Frankfurt am Main 43
Orem 39
Turin 38
Fairfield 37
Redwood City 37
Toronto 36
Changsha 35
West Jordan 35
Mestre 34
Rio de Janeiro 34
San Francisco 34
Haiphong 32
Nanchang 32
Columbus 31
Da Nang 31
Memphis 31
Warsaw 31
Atlanta 30
Brooklyn 30
Denver 30
Nuremberg 30
Seoul 29
Amsterdam 28
Hebei 27
Pune 27
Carrboro 26
San José 26
Seattle 26
Belo Horizonte 25
Stockholm 25
Curitiba 24
Bologna 22
Boston 22
Jiaxing 22
Mexico City 22
San Diego 22
Washington 22
Brasília 21
Tashkent 20
Baghdad 19
Charlotte 19
Sydney 18
Chennai 17
London 17
Nairobi 17
Philadelphia 17
Genoa 16
Shanghai 16
Guatemala City 15
Johannesburg 15
Kingston 15
Lecce 15
Managua 15
Manchester 15
Totale 25.956
Salva come PNG Salva come JPEG
Nome #
Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables 1.221
Step length predicts executive dysfunction in Parkinson’s disease: a 3-year prospective study 1.014
Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients 981
Managing Device-Aided Treatments in Parkinson's Disease in Times of COVID-19 948
Sex Differences in Parkinson’s Disease: From Bench to Bedside 662
Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations 609
Gender differences in microRNA expression in levodopa-naive PD patients 589
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. 554
Gait Analysis in Progressive Supranuclear Palsy Phenotypes. 552
Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study 542
Combined regional T1w/T2w ratio and voxel-based morphometry in multiple system atrophy: A follow-up study 527
Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy 492
Quality of Life and Nonmotor Symptoms in Parkinson's Disease 481
White matter changes and the development of motor phenotypes in de novo Parkinson's Disease 467
Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation 425
Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status 415
Energy expenditure, body composition and dietary habits in progressive supranuclear palsy 406
Apathy evaluation scale-informant version in progressive supranuclear palsy: Psychometric properties and clinical correlates 370
Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada 367
Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review 357
A longitudinal study of cognitive dysfunction in patients affected by Parkinson’s disease with and without freezing of gait 355
Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes 348
Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. 347
Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy 337
Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. 290
Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease 260
Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects 232
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 229
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study 221
Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy 208
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale 202
An easy tool to improve accuracy in pre-diagnostic Parkinson's disease population 196
Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson’s Disease 194
Application of the mPSPRS to the Salerno Cohort and a Comparison Between PSP-RS and vPSP 190
A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease 189
Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers 189
APP-Related Corticobasal Syndrome: Expanding the List of Corticobasal Degeneration Look Alikes 181
Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study 180
Serum miR-30c-5p is a potential biomarker for multiple system atrophy 178
Quitting smoking: An early non-motor feature of Parkinson's disease? 177
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 168
Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy 163
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease 162
The relevance of gender in Parkinson's disease: a review 160
Increased bilirubin levels in de novo Parkinson's disease 160
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease 158
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study 157
Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. 155
Psychometric properties and clinical correlates of the Frontal Behaviour Inventory in progressive supranuclear palsy: data from the PSP-NET 153
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease 151
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? 149
Caffeine consumption and the 4-year progression of de novo Parkinson's disease 149
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. 148
Regional gray matter atrophy in patients with Parkinson disease and freezing of gait 147
Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy 144
Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease 142
Bipolar Disorder and Parkinson’s Disease: A 123I-Ioflupane Dopamine Transporter SPECT Study 142
Gender and non motor fluctuations in Parkinson's disease: A prospective study 139
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: A 4-year longitudinal study 138
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 137
Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards 136
PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family 133
MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes 133
Comparing PIGD and Akinetic-Rigid subtyping of Parkinson Disease and their stability over time 133
Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait. 133
Early MRI findings in acquired hepatocerebral degeneration. 132
Effects of gender on cognitive and behavioral manifestations in multiple system atrophy 132
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease 130
The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy 129
Impact of COVID-19 on neurological patients attending a botulinum toxin service 129
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 128
Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy 128
Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism 127
Non-motor correlates of smoking habits in de novo Parkinson's disease 127
The use of smell identification test in Parkinson's disease in Italy: Preliminary data 127
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Sep;132(Pt 9):2350-5. PMID: 19584099 126
Short-latency afferent inhibition in patients with Parkinson’s disease and freezing of gait 126
Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy 126
Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation 126
Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. 125
Gait patterns in Parkinsonian patients with or without mild cognitive impairment. 124
Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. 124
Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale 122
Clinical trial eligibility in PSP: Population representativeness and potential criteria adjustment based on PSP-NET findings 121
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease 121
Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family 121
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness aspresenting symptoms of PARK-2 119
Midbrain MRI assessments in progressive supranuclear palsy subtypes 119
Agreement between Optoelectronic System and Wearable Sensors for the Evaluation of Gait Spatiotemporal Parameters in Progressive Supranuclear Palsy 118
Uric acid relates to dopamine transporter availability in Parkinson's disease. 118
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 118
Presence and progression of non-motor symptoms in relation to uric acid inde novoParkinson's disease 118
Levodopa-carbidopa intestinal gel is an option in Parkinson’s disease with hyponatremia induced by dopamine agonists 118
Brittle response to levodopa as a marker of Parkinson’s disease phenotype characterized by heavy motor and non-motor burden 117
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients 117
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. 117
Deep Brain Stimulation Target Selection for Parkinson's Disease 116
Efficacy of Safinamide and Gender Differences During Routine Clinical Practice 115
Programming Deep Brain Stimulation for Tremor and Dystonia: The Toronto Western Hospital Algorithms 113
Motor, cognitive and behavioral differences in MDS PSP phenotypes 112
Totale 24.658
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.271
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.271
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022924 0 0 0 0 11 4 18 34 132 117 138 470
2022/20231.387 183 95 70 109 180 309 16 125 189 9 72 30
2023/2024947 52 116 44 65 34 113 42 83 61 78 79 180
2024/20252.692 84 26 46 164 106 233 341 248 465 315 344 320
2025/202620.902 3.579 5.250 4.530 721 1.114 484 1.538 336 556 1.053 292 1.449
2026/20273.013 538 338 911 1.156 70 0 0 0 0 0 0 0
Totale 34.425